FDA Enforcement, Hims & Hers Pullback, Novo Nordisk GLP-1 Lawsuit, Weight-Loss Telehealth Warnings
On February 6, 2026, the U.S. Food and Drug Administration announced it will take enforcement action against non-FDA-approved compounded GLP-1 drugs that are being mass-marketed as alternatives to FDA-approved therapies.
FDA GLP-1 Enforcement Press Release
The FDA said these products lack verified quality, safety, and efficacy and that it will use all available compliance and enforcement tools — including seizures or injunctions — against companies that fail to comply.
“The FDA cannot verify the quality, safety, or effectiveness of these non-FDA-approved compounded GLP-1 products … Entities engaged in mass marketing should be on notice.” — FDA Press Announcement
In regulatory language, the agency also made clear that compounded products cannot be marketed as “generic,” “clinically proven,” or equivalent to approved drugs.
Hims & Hers Pulls Back GLP-1 Weight-Loss Pill
Shortly afterward, Hims & Hers Health abruptly abandoned its plan to launch a compounded version oral weight-loss pill priced as low as $49/month, backing off within days amid regulatory pressure and industry backlash. They had planned a Super Bowl launch announcement.
Reuters coverage:
https://www.reuters.com/legal/litigation/hims-hers-stop-offering-compounded-semaglutide-pill-after-fda-crackdown-2026-02-07/
Novo Nordisk Files Patent Infringement Lawsuit
At the same time, on Monday, Feburary 9, 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers, alleging that the telehealth company’s compounded products infringe U.S. patents for semaglutide — the active ingredient in Wegovy and Ozempic — and that such products threaten patient safety and drug approval integrity.
“Hims has engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.” — Novo Nordisk
Novo is seeking a permanent injunction and damages.
Warning Letters to Telehealth providers marketing GLP-1 compounded
On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites – warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs.
FDA GLP-1 Telehealth Marketing Warning Announcement
In addition to Hims & Hers, these new set of warnings were sent to telehealth companies selling GLP-1 Weight Loss solutions, including: MaxLife, Measured, Zappy, Kin Meds, GoodGirlRx, WeightCare and PharmaZee among others.
Example letter contents included the text:
“Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded.”
Why This Matters
Together, these developments signal renewed enforcement of drug approval and safety standards, alongside aggressive protection of pharmaceutical intellectual property.
- FDA action reinforces that compounded GLP-1 alternatives are not approved drugs
- Hims & Hers’ retreat highlights the business risk when regulatory and legal interests collide with aggressive medical marketing
- Novo Nordisk’s lawsuit underscores how intellectual property protections are being actively enforced in the GLP-1 market.
- Telehealth companies high risk when making claims and branding compounded drugs.
For telehealth companies, compounding pharmacies, and investors, this moment stresses the importance of regulatory compliance, the pitfalls of temporary loopholes, transparent product claims, respect for patent protections, and the need to prioritize patient safety as the weight-loss market continues to expand.
